NeoRich BioPharma Tech Co., Limited
PHBID
$0.45
-$0.43-49.28%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 3.00K | 3.40K | 4.30K | 4.30K | 4.20K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.00K | 3.40K | 4.30K | 4.30K | 4.20K |
| Cost of Revenue | 1.70K | 1.70K | 2.00K | 1.90K | 2.60K |
| Gross Profit | 1.30K | 1.70K | 2.30K | 2.40K | 1.70K |
| SG&A Expenses | 235.70K | 249.90K | 290.80K | 312.30K | 367.00K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 237.50K | 251.70K | 292.90K | 314.20K | 369.50K |
| Operating Income | -234.40K | -248.20K | -288.50K | -309.80K | -365.30K |
| Income Before Tax | -226.40K | -1.00M | -404.00K | -524.30K | -674.30K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.23 | -1.00 | -0.40 | -0.52 | -0.67 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -226.30K | -1.00M | -403.90K | -524.30K | -674.30K |
| EBIT | -234.40K | -248.20K | -288.50K | -309.80K | -365.30K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.68 | -3.04 | -1.39 | -2.00 | -2.71 |
| Normalized Basic EPS | -0.43 | -1.90 | -0.92 | -1.31 | -1.76 |
| EPS Diluted | -0.68 | -3.04 | -1.39 | -2.00 | -2.71 |
| Normalized Diluted EPS | -0.43 | -1.90 | -0.92 | -1.31 | -1.76 |
| Average Basic Shares Outstanding | 1.33M | 1.32M | 1.24M | 1.13M | 1.03M |
| Average Diluted Shares Outstanding | 1.33M | 1.32M | 1.24M | 1.13M | 1.03M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |